Peptides for Gut Motility & Dysmotility — Evidence-Based Overview

How peptide Targets Peptides for Gut Motility & Dysmotility

Gut motility refers to the coordinated muscular contractions that propel food, digestive secretions, and waste through the gastrointestinal tract. Normal motility depends on the precise interplay between the enteric nervous system (often called the "second brain"), interstitial cells of Cajal (the pacemaker cells of the gut), smooth muscle layers, and various hormonal and peptide signals. When this coordination breaks down, the result is dysmotility — a broad category that includes conditions such as intestinal pseudo-obstruction, small intestinal bacterial overgrowth (SIBO) driven by stasis, slow-transit constipation, functional dyspepsia, and post-surgical ileus. Unlike gastroparesis, which specifically affects gastric emptying, these broader motility disorders can involve any segment of the gastrointestinal tract and often reflect systemic disruption of the neuromuscular signaling that governs peristalsis.

Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide that functions as a key neurotransmitter in the enteric nervous system. VIP is released by inhibitory motor neurons in the gut wall and plays a critical role in regulating the relaxation phase of peristalsis — the coordinated pattern of contraction and relaxation that moves contents through the intestine. VIP also regulates intestinal blood flow, mucosal secretion, and has anti-inflammatory properties within the gut wall. Deficiency or dysfunction of VIP signaling has been implicated in several motility disorders. In preclinical models, VIP administration can restore coordinated motility patterns disrupted by inflammation, surgical manipulation, or autonomic neuropathy. VIP also modulates the interstitial cells of Cajal, which generate the slow-wave electrical activity that sets the rhythm for gut contractions.

BPC-157 (Body Protection Compound-157) has demonstrated effects on multiple aspects of gastrointestinal motility in animal studies. It has been shown to counteract the motility-disrupting effects of dopamine agonists, opioids, and serotonin antagonists — pharmacological agents that commonly cause dysmotility in clinical practice. BPC-157 appears to restore normal motility through modulation of the nitric oxide system, dopaminergic pathways, and serotonergic signaling in the gut, all of which are critical regulators of enteric neuromuscular function. It also promotes healing of the enteric nervous system and smooth muscle after injury, which is relevant for post-surgical or post-inflammatory dysmotility. However, the evidence for BPC-157's effects on motility is entirely preclinical, derived from rat and mouse models.

Semaglutide, a GLP-1 receptor agonist with robust clinical data in humans, has complex effects on gut motility. GLP-1 receptors are expressed throughout the gastrointestinal tract and the enteric nervous system. While semaglutide is well known to delay gastric emptying — an effect that contributes to appetite suppression and can worsen pre-existing gastroparesis — its effects on small intestinal and colonic motility are more nuanced. GLP-1 signaling influences intestinal transit time, colonic motility patterns, and the migrating motor complex (MMC), the cyclical pattern of contractions that sweeps the small intestine clean between meals and prevents bacterial overgrowth. MOTS-C is a mitochondrial-derived peptide that activates AMPK, a master metabolic sensor. Mitochondrial dysfunction in smooth muscle and enteric neurons can contribute to dysmotility, particularly in conditions involving metabolic or inflammatory stress. By improving cellular energy metabolism in gut tissue, MOTS-C may support the energy-intensive process of coordinated muscular contraction. Oxytocin, while primarily known for its roles in social bonding and reproduction, has receptors throughout the gastrointestinal tract and influences gut motility, visceral sensation, and the gut-brain axis. Preclinical research suggests oxytocin can modulate colonic motility and reduce visceral hypersensitivity.

It is important to recognize that gut dysmotility is often a symptom of an underlying condition — diabetes, autoimmune disease, connective tissue disorders, neurological conditions, or post-infectious injury to the enteric nervous system — rather than a primary diagnosis. Identifying and addressing the root cause is essential. Peptides should be considered as part of a comprehensive approach that may include dietary modifications, prokinetic medications, pelvic floor therapy for outlet dysfunction, and management of contributing conditions. The evidence base for most peptides in motility disorders remains preclinical, with the notable exception of GLP-1 agonists like semaglutide, which have extensive human data though not specifically for motility improvement as a primary endpoint.